IBEX has won funding from InnovateUK to test the efficacy of its patented technologies to improve the standard X-ray techniques used in routine screening of women for breast cancer.
Mammography is widely used to detect breast cancer. Abnormalities are identified via changes in absorption contrast and assessed subjectively, which can lead to false negative and positive diagnoses, and considerable stress to the patient. In addition, the breast is a radiation-sensitive organ; there is a small risk that radiation-induced cancers may be induced in healthy women screened in this way.
IBEX technology provides contrast based on material composition difference and thus has the potential to better discriminate between adipose and glandular tissue in the breast than by absorption contrast alone. Through gridless scatter removal, IBEX’s approach could also improve image quality at half the present typical patient dose.
Early detection of any cancer is key to being able to treat more effectively and increase the 5-year survival rate. If proven to be successful, IBEX technology would result in a reduction of false negative and false positive results, earlier detection of abnormalities and a significant reduction in the radiation risks associated with X-ray mammography.
About IBEX Innovations Limited
IBEX Innovations Limited (IBEX) is a venture capital backed technology business focused on the commercialisation of patented X-ray detector technology for medical and industrial imaging markets. The IBEX technology, which retrofits to existing X-ray detectors, recovers spectral information normally lost in digital X-ray imaging to classify materials in the sample and deliver improved detection of defects and impurities. IBEX is developing applications for its technology in multiple industrial markets including food inspection and NDT, and for medical radiography where the technology is expected to generate improved diagnostic images at reduced patient dose.
For further information on IBEX, please visit www.ibexinnovations.co.uk
Curvebeam to integrate IBEX Trueview® scatter correction in the LineUp product
IBEX launches project to improve breast cancer diagnoses at reduced patient dose
IBEX’s partner in portable security inspection reports a sharp increase in business
IP Group investment in IBEX recognised as “JEREMIE-Funded Deal of the Decade”
Invitation to Tender for the Provision of a Dedicated High End Simulation Server